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A proper ontological treatment of intolerance—including hypersensitivity—to various substances is
critical to patient care and research. However, existing methods and standards for documenting these
conditions have ﬂaws that inhibit these goals, especially translational research that bridges the two
activities. In response, I outline a realist approach to the ontology of substance intolerance, including
hypersensitivity conditions. I defend a view of these conditions as a subtype of disease. Speciﬁcally, a
substance intolerance is a disease whose pathological process(es) are realized upon exposure to a quan-
tity of substance of a particular type, and this quantity would normally not cause the realization of the
pathological process(es). To develop this theory, it was necessary to build pieces of a theory of patholog-
ical processes. Overall, however, the framework of the Ontology for General Medical Science (which uses
Basic Formal Ontology as its uppermost level) was a more-than-adequate foundation on which to build
the theory.
 2010 Elsevier Inc. All rights reserved.1. Introduction
A proper ontological treatment of intolerance—including aller-
gies or hypersensitivity—to various substances such as food, drugs,
vaccines, and radiocontrast media is critical to patient care and
research. These conditions are common, have potentially fatal
effects if not managed properly, and—because avoidance of repeat
exposure to the particular substance involved remains the main-
stay of management—limit therapeutic choices.
The prevalence of intolerance conditions rivals that of common
diseases. The overall prevalence of hypersensitivity conditions of
all types is approximately 10–15% [1]. This estimate does not in-
clude any other types of intolerance (such as that due to enhanced
gastric motility caused by certain macrolide antibiotics, for
example), yet it rivals the prevalence of diabetes mellitus, which
one recent estimate pegs at 8% [2]. An estimate of the prevalence
of drug-hypersensitivity conditions alone is 7% and 10–20% for
outpatient and inpatient populations, respectively [3]. Food, insect,
and other environmental hypersensitivities account for the
remainder. In addition to drug hypersensitivity, common hyper-
sensitivity conditions include allergic rhinitis, insect hypersensitiv-
ity, food hypersensitivity, and contact dermatitis.
The importance of these conditions is highlighted by the fact
that medical records (both paper and electronic) nearly always
have special sections dedicated to documentation of drug hyper-
sensitivity. These sections of the record are typically prominentll rights reserved.and exist at least in both the history and physical report and the
initial set of orders upon admission to the hospital.
Given the emphasis placed on interoperability of data for pa-
tient care in various federal initiatives, and the criticality of data
standards for conducting translational research, it is essential to
have a standard, coherent ontology of these conditions. This stan-
dard should support both clinical applications, such as drug-allergy
checking in the electronic medical record and research applica-
tions, such as aggregating data across sites to facilitate transla-
tional research.
In this paper, I will argue that existing methods of documenting
these conditions and standards for documenting them electroni-
cally have ﬂaws that inhibit these goals. I will then outline a sys-
tematic approach to the ontology of intolerance conditions and
an implementation of it in the Substance Intolerance Ontology
(SIO).
This work is related to that of Ceusters et al. of their analysis of
adverse drug events for the REMINE ontology [4], in that the man-
ifestation of substance intolerance conditions are often included in
the class of so-called adverse events. However, Ceusters et al. do
not address hypersensitivity conditions or intolerances in their
work. They do however provide a few terms and their deﬁnitions
that are useful in this work.2. The current state-of-the-art and its ﬂaws
The lack of a well-founded treatment of substance intolerances
manifests itself in current approaches to their documentation as
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electronically.
2.1. Documentation of Intolerances
Eliciting ‘allergies’ has long been a component of the standard
patient interview [5]. If the patient reports having an ‘allergy’ to
a particular type of substance—also known as the allergen (e.g.,
penicillin, peanuts), the interviewer will typically ask what ‘reac-
tion’ the patient had to the substance (e.g., rash, anaphylaxis). A
thorough interviewer will also ask about all exposures to the sub-
stance, their duration, whether a reaction occurred, and if so, the
time from exposure to onset of any reaction, and the nature and
duration of the reaction [6].
In the paper-based medical record, clinicians record the infor-
mation so obtained in various places. For patients being admitted
to an inpatient setting, clinicians record allergies in the History
and Physical report and in the admission orders. Outpatient paper
records vary widely, but allergies are typically recorded in a prom-
inent place where they may be viewed easily from visit to visit
(that is, the allergy information is not typically buried in progress
notes which are speciﬁc to each visit).
The information recorded includes the substance to which the
patient is allergic at a minimum. It may also include the reaction
or reactions the patient experienced when exposed to the sub-
stance in the past and the date of (or duration since) the patient
ﬁrst experienced the reaction. If the patient reports no allergies,
then the clinician makes an entry of ‘No known drug allergies’ or
‘No known allergies’ (frequently abbreviated NKDA and NKA,
respectively), to indicate that she asked about allergies and the pa-
tient reported none.
In the electronic world, not much is different. A key consider-
ation is codiﬁcation of the allergen to support drug-allergy check-
ing during physician order entry. To allow entry of free-text
allergens is to gather many entries that could and should have
been coded originally [7]. Usually the allergy section of the elec-
tronic medical record is distinct from other sections of the EMR
such as medication orders, problem list, laboratory results, diagno-
ses, and orders. Many EMRs also allow the user to indicate whether
the ‘allergy’ is a hypersensitivity or intolerance. Some EMRs have
the capability to prevent the entry of medication orders until an al-
lergy history is documented (including NKDA when applicable).
2.2. What’s wrong with how we document today
Despite dedicated sections of the record for ‘allergies’, hyper-
sensitivity conditions appear elsewhere in the record. For example,
seasonal allergies to plant substances such as pollen frequently
appear in the record as diagnoses and/or problems, and not as
‘allergies’. Worse, ICD-9-CM and SNOMED-CT codes exist for
drug-hypersensitivity conditions as well and these codes may
appear on the problem list. For example, ICD-9-CM has 10 codes
under the 3-digit header V14 Personal history of allergy to medicinal
agents. The ICD-9-CM code V14.0 represents Personal history of
allergy to penicillin.
Similarly, laboratory testing for hypersensitivity conditions,
although relatively infrequent, are also present in the record else-
where, namely the laboratory results section. Thus, a laboratory
test that indicates a hypersensitivity condition to ragweed, for
example, will not be present in the ‘allergies’ sections of the record,
nor in the problem list or diagnosis section. The results of skin test-
ing for hypersensitivity conditions often appear only in textual
progress notes or consultant reports.
In addition to this scattering of evidence for hypersensitivity
conditions throughout the record, non-hypersensitivity conditions
frequently appear in the ‘allergies’ section, such as nausea andvomiting associated with erythromycin. Lutomski et al. found that
only 78% of patients with a documented ‘antibiotic allergy’ met
their criteria for a true hypersensitivity condition [8]. Although
evidence for a true, type I IgE-mediated hypersensitivity reaction
to radiocontrast media is increasing [9], many reactions to radio-
contrast media appear to be due to other mechanisms [10].
Although the distinctions may be minimal with respect to current
approaches to management, they are signiﬁcant for research.
This current state of affairs poses fundamental problems for
patient care and research. First, the net effect is that the ‘allergies’
section of the typical medical record is insufﬁciently sensitive and
speciﬁc for identifying hypersensitivity conditions and intolerance
conditions. Second, there is rarely a clear distinction among hyper-
sensitivity conditions and intolerances. These conditions have
different genetic and other biological factors involved in their
pathogenesis. Third, data are recorded in proprietary formats using
proprietary identiﬁers for drugs, other non-drug allergens (such as
food and plant allergens), reactions, and so forth. Thus, health
information exchange and use of clinical data in translational
science are inhibited.2.3. Limitations of current standardization of intolerance information
ICD-9-CM. As mentioned previously, ICD-9-CM has just 10 codes
for hypersensitivity diseases, and none for other types of intoler-
ance disease. It does not have any codes for types of molecules
or the pathological processes they set in motion (e.g., type I hyper-
sensitivity reaction).
SNOMED-CT. SNOMED-CT has ‘concepts’ for the representation
of hypersensitivity diseases, as well as other types of substance
intolerance. For example, it has 91936005 Allergy to penicillin. How-
ever, SNOMED-CT asserts that both the allergy and the allergic
reaction are types of disease. For example, both Allergy to substance
and Allergic reaction to substance are descendants of Disease in the
July, 2009 version. This confusion may arise from the fact that the
current method of documenting allergic conditions is to state as
evidence for their existence what reaction occurred in the past.
Furthermore, SNOMED-CT asserts that the substance causes the
intolerance. However, the allergic condition for example exists in
the absence of substance, so these assertions of causality are
incorrect.
MedDRA (the Medical Dictionary for Regulatory Activities) termi-
nology. Despite being perhaps the most directly relevant artifact
to the task at hand, given its role in the process of regulation of
drug products, MedDRA has numerous ﬂaws that prevent it from
being taken seriously as the basis for an ontological theory of intol-
erance and hypersensitivity. It does not deﬁne its terms [11], it
does not meet desiderata even for medical terminologies [12]
let alone formal ontologies, and not only must great care be taken
when using MedDRA for its intended purpose [13], even greater
care must be taken to adapt it to other purposes [14]. With respect
to substance intolerances, MedDRA fundamentally confuses hyper-
sensitivity conditions with the immune reactions that occur upon
exposure. For example, MedDRA states that Contrast media allergy
and Contrast media reaction are entities (siblings) of the same type:
Allergies to food, food additives, drugs and other chemicals. A key as-
pect of the present work is that it carefully distinguishes hypersen-
sitivity conditions from hypersensitivity reactions.
The NCI Thesaurus has limited representation of substance intol-
erances and makes fundamental mistakes. For example, it states
that serum sickness is a type of delayed-type (or type IV) hypersen-
sitivity, which is incorrect. Serum sickness is a type III hypersensi-
tivity reaction, mediated by antibodies (type IV hypersensitivity
reactions are cellular-mediated immune reactions). The NCI The-
saurus has no representation of type III hypersensitivity reaction.
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adverse drug reactions into the categories of unpredictable reactions
and predictable reactions [15]. The former include hypersensitivity
reactions, whereas the latter include exaggerated physiological
activity such as enhanced gastric motility due to erythromycin.
These terms, however, have an epistemological basis and thus they
do not represent universals. Indeed, genetics research is increas-
ingly enabling the prediction of development of hypersensitivity
to certain types of substances [16].
2.4. A realist approach to the ontology of intolerance
In this work, I build on the realist deﬁnitions of disease, disorder,
and diagnosis of Scheuermann et al. [17] and the Ontology for Gen-
eral Medical Science (OGMS) [18]. OGMS in turn, uses Basic Formal
Ontology (BFO) [19] as its upper level, and the deﬁnitions I present
in thisworkalso adhere toBFOwhere theydonotderive fromOGMS.
The current OGMS deﬁnitions of disorder, disease, pathological
process, and diagnosis are:
Disorder: A causally relatively isolated combination of physical
components that is (a) clinically abnormal and (b) maximal, in
the sense that it is not part of some larger such combination.
Disease: A disposition (i) to undergo pathological processes that
(ii) exists in an organism because of one or more disorders in that
organism.
Pathological process: A bodily process that is clinically abnormal.
Diagnosis: The representation of a conclusion of an interpretive
process that has as input a clinical picture of a given patient and as
output an assertion (diagnostic statement) to the effect that the pa-
tient has a disease of such and such a type.
The term ‘clinically abnormal’ is primitive in OGMS (meaning it
has neither a human-language text deﬁnition nor a deﬁnition in
some logical formalism), but Scheuermann et al. give the following
explication of it [17]:
When we say that some bodily feature of an organism is clini-
cally abnormal, this signiﬁes that it: (1) is not part of the life plan
for an organism of the relevant type (unlike aging or pregnancy),
(2) is causally linked to an elevated risk of either pain or other feel-
ings of illness, or of death or dysfunction, and (3) is such that the
elevated ‘risk’ exceeds a certain threshold level.
Note that this explanation of ‘clinically abnormal’ does not rely
on current medical knowledge, although as with all of science, as
we make new discoveries we may learn that various entities do
or do not meet these criteria. If today’s understanding of ‘clinically
abnormal’ were the basis of OGMS, then OGMS would be frozen in
place and could never evolve to include such discoveries.
With respect to the term ‘bodily process’ used in the deﬁnition
of ‘pathological process’, OGMS is incomplete in two respects. First,
OGMS represents bodily process as a subtype of process (from
BFO), but does not provide an Aristotelian, text deﬁnition for it.
Also, OGMS has no term for a clinically-normal bodily process
(which would be a sibling of pathological process). Whether the
term ‘biological process’ from the Gene Ontology (GO:0008150)
fulﬁlls this need is a current topic of discussion in the development
of OGMS [20].
It is also important to note that at the time of this writing, the
deﬁnition of disorder was undergoing substantial review and dis-
cussion [21]. Nevertheless, the essential notion is that an alteration
in the physical structure and/or make-up of an organism (i.e., dis-
order) disposes the organism to undergo pathological processes,
and this disposition is a disease.
2.5. Initial deﬁnitions
A substance intolerance is a disposition to undergo a patholog-
ical process upon exposure to a quantity of molecules of a certaintype, and this quantity would not normally induce such processes.
Here, I use ‘normally’ as an antonym of ‘clinically abnormal[ly]’. For
example, severe nausea and vomiting due to usual therapeutic
doses of erythromycin is an intolerance, as is a disposition to un-
dergo a true type I hypersensitivity reaction upon exposure to pen-
icillin. However, toxicity due to supra therapeutic doses—such as
hepatic necrosis due to ingestion of a massive quantity of acetami-
nophen—is not an intolerance, as the disposition for this process to
occur is present in nearly every human being.
Under this deﬁnition, an intolerance of a particular type (e.g., a
hypersensitivity to penicillin) is a disease. This view is consistent
with the fact that clinicians document many hypersensitivity con-
ditions such allergic rhinitis on patients’ diagnosis and problem
lists. Intolerances are a special type of disease, however, because
realization of the disposition requires the presence of a foreign
substance at a particular location in the body. If we redeﬁne sub-
stance intolerance in terms of disease, then a substance intolerance
is a disease whose pathological process(es) are realized upon expo-
sure to a quantity of substance of a particular type, and this quan-
tity would normally not cause the realization of the pathological
process(es).
Although the substance in question must be present in the body
for the realization of the disposition, it is not part of the disorder
that is the physical basis of the intolerance. Otherwise, the distinc-
tion between persons allergic to penicillin and persons not allergic
to penicillin, for example, would become blurred. Furthermore, if
we considered the substance as part of the disorder, each hyper-
sensitivity reaction would be a new disease particular, since the
body nearly always clears the substance between exposure events.
A patient with a history of three reactions to penicillin-class anti-
biotics would have a history of three different disease particulars,
each self-limited. But in reality, there are three hypersensitivity-
reaction particulars, each a realization of an underlying hypersen-
sitivity disease and hence the foreign substance is not part of the
disorder.
Thus, the intolerance disease exists in the absence of the sub-
stance. That is, persons with hypersensitivity to penicillin, for
example, predictably undergo pathological processes upon expo-
sure to penicillin, whereas persons without penicillin-hypersensi-
tivity disease do not.
This view is slightly more counterintuitive for intolerance dis-
eases that do not involve hypersensitivity reactions, because
hypersensitivity diseases require previous exposure to the sub-
stance for the underlying disorder to develop (see below). Under
these deﬁnitions, we say that an individual has an intolerance dis-
ease even if she is never exposed to the substance in question and
thus never suffers any untoward effects of the disease. Indeed, no
human being need ever discover a disease (disposition) for it to ex-
ist. For example, even if Jane Doe never ingests erythromycin or
any other macrolide-type antibiotic or compound, she has a dis-
ease if such ingestion, had it occurred at a ‘clinically normal’ quan-
tity, would have induced severe nausea and vomiting. This
situation is additionally a consequence of the view of disease as
a disposition. Dispositions exist even if they never are realized [22].
Nevertheless, the view of substance intolerances as diseases,
and diseases as dispositions, is consistent with current research
and approaches to adverse drug events. Indeed, identiﬁcation of
genetic bases for dispositions to adverse drug events, to prevent
the realization of intolerance diseases by preventing or reducing
exposure to certain drugs in certain individuals, is an ongoing area
of active and promising research [23].
Note that SNOMED-CT also takes the view that intolerance and
hypersensitivity are subtypes of disease. However, SNOMED-CT
represents the realization of hypersensitivity diseases, hypersensi-
tivity reactions, as diseases, also. I reject this view as a disposition
is a dependent continuant under BFO, and dependent continuants
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a disposition, nor vice versa. Thus, a hypersensitivity reaction is not
a disease, but the disposition to undergo a hypersensitivity reac-
tion is.
2.6. Classiﬁcation of substance-intolerance diseases
There are at least three possible major axes along which one
might classify substance-intolerance diseases. The ﬁrst possible
axis is the type of pathological process towards which the affected
individual has a disposition. For example, one subtype of intoler-
ance disease is based on immunologically-mediated hypersensitiv-
ity reactions, and hypersensitivity disease may then be further
divided into subtypes of type I, type II, type III, and type IV based
on the corresponding types of hypersensitivity reaction. The sec-
ond possible axis for classifying intolerance disease is the location
in the body where the process occurs. For example, one could dis-
tinguish intolerance diseases that affect the skin (contact dermati-
tis), the nasal mucosa (allergic rhinitis), and the eye (seasonal
allergic conjunctivitis). Finally a third possible axis is the type of
substance (i.e., type of molecule) to which the organism is intoler-
ant. For example, one could distinguish between penicillin allergy
(type I hypersensitivity to all penicillin-class molecules) and sul-
fonamide allergy.
Note that there is interaction among the three axes. The loca-
tion is usually where the substance ﬁrst comes into contact with
the body, and thus localized hypersensitivity reactions occur in
proximity to the site of exposure (e.g., nasal mucosa). Plus some
substances are more likely to enter the body at particular locations
than others, for example, plant pollens via the air.
2.7. Pathological process
Because the type of pathological process involved is more char-
acteristic of substance-intolerance diseases than the particular
type of substance, my ﬁrst distinction among its subtypes is based
on the pathological process. At present, however, no ontology of
pathological processes exists. Thus, I created a high-level ontology
of pathological processes with a view to the classiﬁcation of sub-
stance-intolerance diseases. This classiﬁcation of pathological pro-
cesses therefore may be inadequate or gloss over distinctions
necessary to an overall theory of pathological processes.
The ﬁrst major distinction I make among pathological processes
is between those processes that lead to injury (injuring processes)
and the pathological counterparts to physiological processes (path-
ophysiological processes). Besides injuring processes, there are
other types of pathological processes that are not pathophysiolog-
ical processes, and thus these two direct subtypes of pathological
process are not be exhaustive. Regardless, other subtypes of path-
ological process are not necessary for the remainder of the theory I
present here.
I adopt for my deﬁnition of injuring (or injury process—I use the
gerund form to distinguish the injury process from the injury con-Table 1
Deﬁnition of injuring (harm) as taken from Ceusters et al. [4].
Term Parent Deﬁnition
Structure integrity Qualitya [An] aspect of an anatomical structur
structure. . .either (1) itself becomes[s
Structure change Processa [A process of] change in an anatomica
Integrity change Structure
change
[A structure change that brings] abou
would become dysfunctional or cause
Injuring (harm, per
Ceusters et al.)
Integrity
change
[An] integrity change bringing about a
of [the organism] under which the an
structure. [emphasis added]
a Term is deﬁned in Basic Formal Ontology.tinuant created by the process) the deﬁnition of harm developed by
Ceusters et al. [4]. Thus, in this work, harm and injuring are syn-
onyms. Because both the present work and the work of Ceusters
et al. both use BFO as an upper-level ontology, the reuse of the lat-
ter in the former is straightforward. Ceusters et al. build up their
deﬁnition of harm from their deﬁnitions of structure integrity, struc-
ture change, and integrity change (Table 1).
The alteration in structure integrity produced by an injuring
(i.e., the injury) may be reversible or irreversible, depending on
whether other processes are able to repair the damage or in the
language of Ceusters et al., reduce the range of circumstances un-
der which the structure becomes dysfunctional or causes
dysfunction.
Various types of injuring processes include toxic injuring, an-
oxic injuring, and viral injuring. Note that I am not concerned here
with injuring processes that result, for example, from electromag-
netic radiation. However, if BFO considers electromagnetic radia-
tion as a continuant, then what follows could readily be adapted
to represent various intolerances to electromagnetic radiation,
such as photosensitivity and photophobia.
With respect to exogenous substances then, I am concerned
only with toxic injuring. A toxic injuring (or toxic injury process)
is an injuring due to direct interaction of exogenous molecules
(a.k.a. xenobiotics) with the anatomical structure. Note that inju-
rings thus do not subsume infectious diseases which are, roughly,
the direct interaction of microorganisms with anatomical struc-
tures, which in turn means that injuring and pathophysiological
process (which I treat in detail next) are not exhaustive in covering
the subtypes of pathological process. Toxic inuring may be further
subdivided on the basis of whether the substance itself—directly
toxic injuring—or a chemically-modiﬁed form of the substance that
is generated by the metabolism of the organism—metabolite-medi-
ated injuring—is responsible for the injuring.
The deﬁnition of pathophysiological process requires careful
analysis. First, as stated previously, OGMS does not deﬁne ‘bodily
process’ nor does it contain a term ‘physiological process’,
let alone provide a deﬁnition for one. The notion of process is that
of change: continuants come into existence, go out of existence,
gain and lose parts, gain and lose qualities and dispositions, and
in the case of qualities, change values (e.g., from blue to red, from
50 kg to 55 kg). The continuants that participate in processes may
effect change, undergo change, or both. For example, in the process
of glycogenolysis, glycogen undergoes change by losing glucose
molecules whereas glycogen phosphorylase (among other en-
zymes) effects the change (by removing glucose molecules from
glycogen). Processes can regulate other processes only through
physical changes in the participants of the regulated process. For
example, glycogenolysis is regulated (in part) through structural
changes to glycogen phosphorylase.
In physiological processes, normal anatomical entities cause
and undergo changes in such a way that their qualities stay within
a certain range of values. OGMS uses the term ‘homeostasis’ to cap-
ture this notion, referring to it as . . .the disposition of the . . .organisme [the] deviation from which would bring it about that the anatomical
] dysfunctional or (2) cause[s] dysfunction in another anatomical structure
l structure of a person
t a change in the range of circumstances under which the anatomical structure
dysfunction in another structure
n expansion in the range of circumstances of the sort typically occurring in the life
atomical structure would become dysfunctional or cause dysfunction in another
30 W.R. Hogan / Journal of Biomedical Informatics 44 (2011) 26–34. . .to regulate its bodily processes in such a way as (1) to maintain
bodily qualities within a certain range or proﬁle and (2) to respond
successfully to departures from this range. . .[17].
Injurings differ from pathophysiological processes then, in that
injurings are structural changes to normal physical components of
the organism from the outside that result in disorders, and patho-
physiological processes then are the realization of such disorders;
that is, they are the abnormal functioning of anatomical entities
modiﬁed in abnormal ways.
I can now deﬁne a pathophysiological process as a pathological
process that is the realization of those disorders that result from
structural changes to normal anatomical entities (as opposed to
those disorders that result from the abnormal presence of exter-
nal entities). The use of ‘clinically abnormal’ in the deﬁnition of
disorder ensures that, for example, the damage to a few liver cells
caused by a few milligrams or less of acetaminophen is not a dis-
order, and thus the realization of this damage (reduced function-
ing of hepatocytes) does not constitute a pathophysiological
process. In other words, the body corrects damage all the time
without that damage and the processes that result from that
damage reaching the level of risk of feelings of illness, death, or
dysfunction required for clinical abnormality. Thus, one should
not assume that every process resulting from exogenously-in-
duced structural change in the body constitutes a pathophysio-
logical process, but only those structural changes that are types
of disorder.
Pathophysiological processes may be subdivided into exagger-
ated realizations of a biological function and suppressed realiza-
tions of a biological function. Before deﬁning these terms, it will
be useful to review the BFO deﬁnition of ‘biological function’ and
how biological functions are realized as processes. Arp and Smith
[24] ﬁrst deﬁne ‘function’ as:
(1) a realizable dependent continuant. Thus,
(2) it has a bearer, which is an independent continuant, and
(3) it is of a type instances of which typically have realizations;
each realization is:
a. a process in which the bearer is participant
b. that occurs in virtue of the bearer’s physical make-up,
c. and this physical make-up in something which that
bearer possesses because of how it came into being.They then deﬁne ‘biological function’ as a function which in-
heres in an independent continuant that is (i) part of an organism
and (ii) exists and has the physical structure it has as a result of the
coordinated expression of that organism’s structural genes [24].
The key notion from these deﬁnitions is that a function is real-
ized as a process, and exists even if it is not being realized. For
example, the enzyme glycogen phosphorylase has the function to
cleave glucose molecules from glycogen even when unable to carry
out that function due to having undergone dephosphorylation
which inactivates it.
An exaggerated realization of a biological function (or synony-
mously, an exaggerated biological functioning) is a pathophysio-
logical process involving an abnormally large number of—or
abnormal location of—the participants in the realization of a bio-
logical function. The increased number of participants—or the
abnormal location of participants—is the structural change men-
tioned in the deﬁnition of pathophysiological process. For example,
excess insulin in the blood of Jane Doe (disorder) due to an insulin-
producing tumor results in exaggerated insulin-receptor binding at
muscle and fat cells (i.e., there is an increased number of insulin
and insulin-receptor participants), which in turn increases the
number of active glucose transporters in those cells (disorder),
which in turn results in an exaggerated process of glucose uptake
from blood into those cells (increased number of transporters par-ticipating), which in turn results in an abnormally low number of
glucose molecules in the blood (Jane’s hypoglycemia disorder).
A suppressed realization of a biological function (or synony-
mously, a suppressed biological functioning) is a pathophysiologi-
cal process involving an abnormally small number of participants
in the realization of a biological function. For example, a deﬁciency
of insulin in the blood of John Doe (disorder) due to absence of beta
cells in the pancreas (as in type 1 diabetes mellitus) results in a
suppressed insulin-binding process in muscle and fat cells, which
in turn reduces the number of active glucose transporters (disor-
der), which in turn results in a suppressed process of glucose
uptake into those cells (decreased number of transporters partici-
pating), which in turn results in an abnormally high number of
glucose molecules in the blood (John’s hyperglycemia disorder).
Note that a suppressed process cannot be the complete cessa-
tion of functioning; otherwise since no process exists the term
would not refer to anything in this case. Instead, complete
cessation of functioning must instead be handled as a process of
complete inhibition, which itself may either be a novel, extraphys-
iological process or a pathophysiological process if it is the case
that an increased number of participants in a normal inhibitory
process reduces the number of participants in the regulated pro-
cess to zero (or near zero). One example of a process of complete
inhibition of functioning is the irreversible proton-pump inhibition
of certain types of benzimidazole compounds (such as omepra-
zole), which reduces towards zero the number of proton-pumps
(in gastric parietal cells) that participate in the excretion of protons
(H+ ions) into the gastric lumen. Since this inhibition is not the
realization of a biological function, it is an extraphysiological
inhibition.
An exaggerated immune reaction is an exaggerated realization of
a function of the immune system in response to exposure to a par-
ticular type of molecule. Exaggerated immune reactions may be
further subdivided into antibody-mediated hypersensitivity
reactions, immune-cell-mediated hypersensitivity reactions, and
anaphylactoid reactions. An antibody-mediated hypersensitivity
reaction is an exaggerated immune reaction due to speciﬁc binding
of antibody and the type of molecule involved (i.e., antigen). I dis-
cuss the deﬁnitions of antibody, antigen, and speciﬁc binding be-
low. The ﬁrst three types of hypersensitivity reaction (types I, II,
and III) are all subtypes of antibody-mediated injuring. A cell-med-
iated hypersensitivity reaction is an exaggerated immune reaction
due to binding of antigen by receptors on T lymphocytes. The term
‘cell-mediated hypersensitivity reaction’ is synonymous with ‘type
IV hypersensitivity reaction’. An anaphylactoid reaction is a an
exaggerated immune reaction due to stimulation of histamine re-
lease from mast cells either through non-speciﬁc antigen binding
of the Fc component of IgE (immunoglobulin type E) [10].
2.7.1. Pathophysiological processes and the Gene Ontology
The biological process taxonomy of the Gene Ontology has rep-
resentations of tens of thousands of normal physiological processes
and biological functions. One could combine these terms with
pathophysiological process, exaggerated realization of a biological
function, or suppressed realization of a biological function to repre-
sent pathophysiological processes. Note that as yet, the only rela-
tion formally approved in the Relation Ontology for connecting
occurrents in this manner is the preceded_by relation [25], which
is too weak to capture fully the notion of increased or reduced par-
ticipation (or abnormal change in location of participation) in the
realization of a biological function..
This combination of terms could occur either in a pre-coordi-
nated fashion in a pathophysiological-process ontology, in a post-
coordinated fashion, or in some mixture of the two. The combina-
torial explosion of the ﬁrst approach is undesirable; the preferred
approach of the Open Biomedical Ontologies (OBO) Foundry is to
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post-hoc using methodologies like that of Mungall et al. [27].
Another potential issue with respect to hypersensitivity and the
Gene Ontology is that hypersensitivity reactions of all types are
pathological processes (hence the word hypersensitivity), but the
Gene Ontology—despite an objective of representing only normal
processes—has representations of them. For example, GO:0001802
is the identiﬁer for type III hypersensitivity in the biological process
taxonomy. Thus, one might argue that these terms ought to be
moved out of the Gene Ontology into whatever ontology of patho-
logical processes the OBO Foundry ultimately adopts. The intention
of this work is not to advocate one way or the other, but merely to
point out the potential difﬁculty.
2.7.2. Deﬁnitions and considerations speciﬁc to hypersensitivity
disease
The termantigendoesnot refer toanyparticular typeofmolecule,
but rather the role a molecule plays in binding to immunoglobulin
molecules. Antibody is generally synonymous with immunoglobulin,
and refers to molecules produced by immune cells that have the
function of binding foreign molecules of a speciﬁc type. Allergen is
a type of antigen role played by a molecule or portion of molecules
of a given type in either inducing a hypersensitivity disease where
none previously exists or in inducing a hypersensitivity reaction
where a hypersensitivity disease does exist. The literature does
not seem to distinguish the two, but one could easily create sub-
roles of allergen: sensitization allergen and reaction-induction aller-
gen. These sub-rolesmight be of valuewhen themolecules that have
the role of sensitization allergen are of a different type than themol-
ecules that have the role of reaction-inductionallergen (for example,
the patient may have been sensitized upon exposure to amoxicillin,
but reacted to another penicillin-type molecule such as piperacillin
or even to a cephalosporin-type molecule such as cefazolin).
The antibody binds only with particular parts of the allergen
molecule. An epitope or antigenic determinant is therefore the role
played by a part of a molecule of binding with an antibody. The
analogous role of the binding part of the antibody molecule is
the antigen-binding region.
2.8. Location of pathological process
The location or tissues in which the pathological process occurs
is also a common axis of classiﬁcation of substance intolerances.
For example, hypersensitivity diseases include allergic rhinitis
(nose), allergic conjunctivitis (eye), contact dermatitis (skin), aller-
gic vasculitis (a type III hypersensitivity reaction occurring in blood
vessels), and so on. The key notion is that that the pathological pro-
cess is localized to a particular part of the body. For hypersensitiv-
ity reactions, this location is frequently the location where the
exogenous substance enters the body. In the case of allergic rhini-
tis, for example, airborne allergens come into contact with the na-
sal mucosa and induce mast-cell responses there.
Conversely, some hypersensitivity reactions are systemic, such
as that involved in anaphylaxis. In both the case of allergic rhinitis
and anaphylaxis, a type I hypersensitivity reaction is involved, but
the extent of the reaction differs. The route of exposure involved
may increase the severity of the reaction, but anaphylaxis is not
limited to intravenous exposure to allergen and occurs with oral
ingestion and cutaneous injection (e.g., Hymenoptera stings), for
example.
With respect to other types of intolerances, these too may be
localized vs. systemic. For example, a well-known toxicity of ami-
odarone, to which some individuals are more susceptible than oth-
ers, is pulmonary toxicity.
One might ask what constitutes an exposure and what types of
exposure are necessary to initiate a pathological process. For exam-ple, in the case of type 1 hypersensitivity reactions the molecules
of the portion of substance must enter the body deeply enough
to bind with immunoglobulin E molecules on the surface of mast
cells. Other substance intolerances might require greater or lesser
penetration of the substance into the body to trigger pathological
processes. Also, note that not every instance of exposure (to a cer-
tain quantity of substance at a particular location in the body) need
initiate a pathological process. There is a disposition to undergo
pathological processes upon exposure, meaning that there is an
elevated risk—but not certainty—of the pathological process occur-
ring upon exposure.
2.9. Type of substance
Clinically, the type of substance that induces pathological pro-
cesses has been the most important aspect of intolerance diseases
to record, because avoidance of repeat exposures is the mainstay of
treatment. Fortunately, it is also the easiest aspect to determine
and remember. It is usually difﬁcult to determine with certainty
which type of process occurred (except perhaps in the case of ana-
phylaxis but even then the underlying reaction is not always a type
I hypersensitivity reaction), which clinicians often infer indirectly
from the clinical manifestations of the reaction (i.e., rash, anaphy-
laxis, etc.).
In addition, intolerance to one type of molecule also often
means that an organism will not tolerate structurally related types
of molecules. Thus, a patient who experienced a reaction to amox-
icillin should not be given any penicillin-class antibiotic (such as
piperacillin), as the risk of a life-threatening hypersensitivity reac-
tion is high. Nearly all macrolide antibiotics enhance gastric motil-
ity to some degree, and thus a patient with severe nausea and
vomiting due to erythromycin has an increased risk of the same
due to clarithromycin, for example.
Note that in these cases there is one instance of substance intol-
erance disease. The individual is intolerant to several types of mole-
cule that share a particular sub-structure, where that sub-structure
is responsible for initiating the pathological process that occurs. In
the case of hypersensitivity reactions, this shared sub-structure that
binds to immunoglobulin is the epitope (deﬁned above). With re-
spect to the most common form of penicillin-class antibiotic hyper-
sensitivity, the shared beta-lactam ring structure (speciﬁcally, one
of its key metabolites) is the epitope. The penicillin-allergic patient
may be allergic as well to other classes of antibiotic that also have a
beta-lactam ring, for example cephalosporins and carbepenems
[15].
It is common to classify intolerances, especially hypersensitivity
diseases, by broad headings such as food vs. drug vs. plant vs. in-
sect allergy. In the case of the ﬁrst two headings, the designation
of food and drug refer to a role that the portion of substance has.
A peanut allergy, for example, is a hypersensitivity disease in re-
sponse to particular proteins (or epitopes of these proteins) con-
tained within the peanut. Peanuts themselves have the role of
food (or at least numerous instances of peanut do). In the cases
of plant allergy and insect allergy, the hypersensitivity is to some
protein (or various epitopes of it) that is part of the plant or insect,
not the entire plant or insect itself. In the case of insects, it is often
the venom of an insect that is the allergen, and hence clinicians
sometimes use the term venom allergy.
In this work, I make food, drug, and venom a subtype of the term
role of portion of substance, which I represent as a child of the BFO
term role. These terms ultimately belong in OGMS or another
ontology because their deﬁnitions have broader implications and
uses beyond that required for modeling substance-intolerance dis-
eases. I therefore do not attempt to deﬁne them or more speciﬁ-
cally classify them in this work. Finally, as a consequence of
these facts, the terms food hypersensitivity, drug hypersensitivity,
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tivity all represent deﬁned classes and not universals, so deﬁnitions
of these terms are not essential to the core theory I introduce here,
despite their common usage in patient care and public health.3. The Substance Intolerance Ontology
I implemented the theory as a representational artifact using
the above deﬁnitions in the OBO format using OBO-Edit v2.0. The
primary reason for the choice is that OGMS is maintained in
OBO. Interconverters between OBO format and the Web Ontology
Language (OWL) are available. The curators of OGMS use these
converters to release an OWL version of OGMS.
The top-level of the hierarchy underneath substance intoler-
ance disease reﬂects the pathological processes involved, per the
theory as described above (Fig. 1). I include the human-readable,
Aristotelian deﬁnitions from the theory with each term in the
ontology. Below substance intolerance, each type of disease has a
deﬁnition of the form: a substance intolerance disease whose real-
ization is a <pathological process> process. If the type of substance
is mentioned, then the template expands to: a substance intoler-
ance disease whose realization is a <pathological process> process
upon exposure to <substance>.
I also included in SIO the pathological processes I deﬁne here
(Fig. 2). At present, no relation exists in the Relation Ontology thatFig. 1. The hierarchy from BFO down to substconnects a disposition with the process that realizes it. Thus, I in-
serted a placeholder relation to connect them until the Relation
Ontology has an appropriate relation to use instead.4. Discussion
Using the framework of Basic Formal Ontology and the Ontol-
ogy for General Medical Science, I have developed an ontological
theory of substance intolerance that views these conditions as dis-
eases. I implemented it in a representational artifact, the Substance
Intolerance Ontology (SIO). Speciﬁcally, I defended the view that a
substance intolerance disease is a disposition to undergo patholog-
ical processes upon exposure to a quantity of a substance, and this
quantity would not normally cause such a reaction. The theory
makes a careful distinction between a disposition to undergo
particular processes, and the processes themselves. Pre-existing
terminological artifacts such as SNOMED-CT and MedDRA fre-
quently blur this important distinction. I also reviewed and incor-
porated the three major axes on which these diseases are typically
classiﬁed: the pathological process to which the organism is dis-
posed, the location within the organism where the pathological
process occurs, and the substance that induces the pathological
process.
Note that a consequence of the OGMS deﬁnition of a disease as a
disposition means that organisms have a disease even if they neverance intolerance disease and its subtypes.
Fig. 2. The pathological process hierarchy.
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ease. With respect to substance intolerance, a person has a disease
even if he or she is never exposed to the substance and even if the
likelihood of exposure is minimal. For example, if I am more sensi-
tive than the human race as a whole to some novel compound in
outer space, I have a disease. The risk of feelings of illness, dysfunc-
tion, and death that is part of the notion of clinical abnormality is
not the same risk as that of being exposed to the substance. The risk
of exposure to a penicillin-class antibiotic might be quite high, for
example, in a patient admitted to the hospital with community-ac-
quired pneumonia, and yet the risk of undergoing a pathological
process as a result may approach zero in the absence of any hyper-
sensitivity condition or other intolerance. Conversely, the risk of
undergoing a pathological process might be quite high given expo-
sure, but the risk of exposure quite small. Indeed, reducing the risk
of subsequent exposures in the setting of hypersensitivity
conditions is, as I have already pointed out, the mainstay of
management.
This work identiﬁed several unfulﬁlled dependencies at a level
of general ontological theory. First, this work suggests that the
absence of a robust ontological theory of pathological processes
could impede the development of the ontology of disease in gen-
eral. In this work, it was additionally necessary to develop enough
of such a theory as to accommodate intolerance disease. This work
can inform efforts to address the need, but is almost certainly inad-
equate in and of itself to fulﬁll the need. In addition to the need for
an ontology of pathological processes, this work identiﬁed gapsthat might be ﬁlled by the Ontology for General Medical Science.
Speciﬁcally, non-disease speciﬁc deﬁnitions of food, drug (medica-
tion), antibiotic, and venom are needed at a minimum. Finally, a
relation that connects types of disease to types of pathological pro-
cess is needed in the Relation Ontology.
Finally, I motivated the need for SIO by discussing the limita-
tions of current approaches to representing instances and types
of substance intolerances. One key limitation that this theory
addresses is confusing and conﬂating the reactions to exposure
(occurrent) with the disposition to undergo those reactions
(dependent continuant). I have also highlighted the fact that the
most common form of documentation of any particular intolerance
disease in a particular patient is documenting details of past
reactions. However, evidence for intolerance diseases often exists
elsewhere in the record in other forms such as in problem lists, lab-
oratory data, the results of skin testing (for hypersensitivity condi-
tions), and so on. Uniﬁcation of all the evidence in medical records
for intolerance diseases is at present not possible because existing
methods do not properly link these diseases with their evidence
and often equate diseases with one form of evidence (typically
reactions). By clarifying the essential nature of intolerances and
their manifestations, and linking them together in an overall
coherent theory, the SIO should enable the development electronic
medical records and informatics systems in support of clinical and
translational research that can return a list of all intolerance dis-
ease particulars in a given patient or population, regardless of what
evidence exists for them.
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This work has several limitations. First, the theory does not yet
address the clinical manifestations of various pathological pro-
cesses. For example, hypersensitivity reactions variably cause
hives, rash, urticaria, fever, etc. Addressing this limitation requires
further development of a theory of signs and symptoms and their
relationships to pathological processes. OGMS is in the very early
stages of addressing this need, which clearly has much broader
applicability than the theory of substance intolerance I defend
here. Second, this work was limited by an absence of an ontological
theory of pathological processes, as discussed. As such a theory
evolves, it could substantially change the hierarchical organization
of substance-intolerance diseases I created. Nevertheless, so long
as the relationships between intolerance diseases and pathological
processes are present, a classiﬁer could automatically reorganize
the intolerance disease hierarchy as the pathological process hier-
archy undergoes revision. Finally, at present, the SIO does not meet
the OBO Foundry criterion of having a community of users. This
paper is intended to serve as the foundation for the formation of
such a community.
4.2. Future work
Filling out the SIO will require composition of terms from SIO,
from the Chemical Entities of Biological Interest (ChEBI) ontology
to denote the type of substance, from a pathological process ontol-
ogy to denote the pathological process, from a symptom ontology
to denote clinical manifestations, and from the Foundational Model
of Anatomy ontology to denote anatomical locations. This compo-
sition might be facilitated from the creation of templates. For
example, developers of the Ontology of Biomedical Investigations
have created a template for easily generating new terms to denote
laboratory observations [28]. Also, to operationalize a realist ap-
proach to the recording of data about substance-intolerance dis-
eases in patients or subjects of research will almost certainly
require integration with a system such as the Referent Tracking
system of Ceusters and Smith [29]. Development of a set of referent
tracking templates that could be used for documenting substance-
intolerance diseases, the reactions that have occurred, their clinical
manifestations, and the substances involved would likely facilitate
the integration.
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